Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients.
Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients.
复制标题
DOI：
10.3816/cbc.2002.n.008
复制
发表时间：
2002-01-01
影响因子：
3.1
通讯作者：
Dirix, Luc Y
中科院分区：
文献类型：
--
作者：
Benoy, Ina;Salgado, Roberto;Dirix, Luc Y
对健康对照 (n = 26)、患有局部疾病的乳腺癌患者 (n = 31) 和进展期疾病患者 (n = 73) 的血液中血管内皮生长因子 (sVEGF 和 pVEGF) 的血清和血浆浓度、白细胞介素 6 (IL-6) 的血清浓度和 VEGF 血小板载量 (VEGF/pl) 进行了比较。对照群体的第 95 个百分位值为 sVEGF 250 pg/mL、pVEGF 30 pg/mL 和 IL-6 1.6 pg/mL。对照人群中计算出的 VEGF/pl 的第 95 个百分位值为 1.0 pg/10(6) 血小板。所有组中血清 VEGF 浓度与血小板数量相关。血小板增多症患者的中位 sVEGF 浓度为 833 pg/mL，而其他患者的中位 sVEGF 浓度为 249 pg/mL (P = 0.018)。血清IL-6水平与sVEGF水平和计算的VEGF/pl相关。与健康对照相比，乳腺癌患者的血清 IL-6 浓度显着升高（P < 0.0001）。与局部区域疾病患者相比，转移性乳腺癌患者的中位 IL-6 血清水平高出近 10 倍（分别为 6.0 pg/mL 和 0.7 pg/mL）。血浆 VEGF 和 VEGF/pl 在 3 组中也有显着差异。与局部区域疾病患者相比，转移性乳腺癌组的 sVEGF 和 pVEGF 之间的比率往往较小（中位数分别为 7.5 比 10.1；P = 0.066），表明转移性乳腺癌组中血管内血小板脱粒较多。血清 IL-6 水平是区分健康对照与局部和转移性乳腺癌患者组的最具区别性的因素。这些结果表明肿瘤源性 IL-6 在调节血小板及其前体中 VEGF 表达中的作用，并且还证实了循环血小板在 VEGF 储存中的作用。
Serum and plasma concentrations of vascular endothelial growth factor (sVEGF and pVEGF), serum concentrations of interleukin 6 (IL-6), and VEGF platelet load (VEGF/pl) in the blood of healthy controls (n = 26), breast cancer patients with locoregional disease (n = 31), and patients with progressive advanced disease (n = 73) have been compared. The 95th percentile values for the control population were 250 pg/mL for sVEGF, 30 pg/mL for pVEGF, and 1.6 pg/mL for IL-6. The 95th percentile value of the calculated VEGF/pl was 1.0 pg/10(6) platelets in the control population. Serum VEGF concentrations correlated with platelet number in all the groups. Patients with thrombocytosis had a median sVEGF concentration of 833 pg/mL, compared to 249 pg/mL in other patients (P = 0.018). Serum IL-6 levels correlated with sVEGF levels and with the calculated VEGF/pl. Serum IL-6 concentration was significantly higher in patients with breast cancer compared to healthy controls (P < 0.0001). Median IL-6 serum levels were nearly 10 times higher in patients with metastatic breast cancer as compared to the those with locoregional disease (6.0 pg/mL versus 0.7 pg/mL, respectively). Plasma VEGF and the VEGF/pl were also significantly different in the 3 groups. The ratio between sVEGF and pVEGF tended to be smaller in the metastatic breast cancer group compared to the patients with locoregional disease (median, 7.5 versus 10.1, respectively; P = 0.066), suggestive of more intravasal platelet degranulation in the former group. Serum IL-6 level is the most discriminative factor separating healthy controls and the locoregional and metastatic breast cancer patient groups. These results suggest a role for tumor-derived IL-6 in regulating VEGF expression in platelets and their precursors and also confirm the role of circulating platelets in the storage of VEGF.